Improving economic conditions and a more favorable regulatory environment give Goldman Sachs catalysts to benefit from in the ...

Hedge funds are making some adjustments to their tech-investing playbook.

He said that hedge fund ownership of potential deregulation beneficiaries, stocks with small business exposure, and domestic ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

Goldman Sachs warned there's a risk of a 5% slump in US stocks because ... retreated after President Trump imposed an additional 10% tariff on Chinese goods. Moderna (MRNA) closed down more than -7% ...

China is starting to see a rebound in M&As as government stimulus measures start to bear fruit and pressure from Donald Trump ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

In a report released on February 14, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

CSL and Cochlear are two of Australia’s blue-chip healthcare stocks, stalwarts of many investors portfolios, whereas Pro ...

New orders also cascaded 16.4 points lower, though were still positive at 17.8. Barclays downgraded Moderna shares to equal ...

Investors seeking to outperform the market should focus their stock-picking efforts on volatile names in the consumer ...

Please be advised, today's conference is being recorded. I would now like to hand the conference over to your speaker today, Lavina Talukdar. Please go ahead. Thank you, Kevin. Good morning, everyone, ...